- 专利标题: FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF
-
申请号: US18036144申请日: 2021-11-11
-
公开(公告)号: US20240352139A1公开(公告)日: 2024-10-24
- 发明人: Xin GAO , Niliang QIAN , Xiujie PAN , Guili XU , Yujie LIU , Hongjie LI , Cuima YANG , Qinzhi XU , Xiaoqian DOU , Yunhui LIU , Zhenjun YU , Guijun BAI
- 申请人: BEIJING IMMUNOAH PHARMATECH CO., LTD.
- 申请人地址: CN Beijing
- 专利权人: BEIJING IMMUNOAH PHARMATECH CO., LTD.
- 当前专利权人: BEIJING IMMUNOAH PHARMATECH CO., LTD.
- 当前专利权人地址: CN Beijing
- 优先权: CN 2011253989.9 2020.11.11
- 国际申请: PCT/CN2021/130015 2021.11.11
- 进入国家日期: 2023-05-09
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61P35/00 ; C07K16/30
摘要:
The present application provides a fusion protein, containing: an anti-CD137 antibody capable of specifically binding to a CD137 molecule or an antigen binding fragment thereof; an anti-CD3 antibody capable of specifically binding to a CD3 molecule or an antigen binding fragment thereof; and a first peptide linker and a second peptide linker. The present application also provides a nucleic acid encoding the fusion protein, an expression vector containing the nucleic acid, a host cell containing the nucleic acid or the expression vector, a method for preparing the fusion protein, a pharmaceutical composition containing the fusion protein, and a use of the fusion protein.
信息查询